This data significantly de-risks the zovegalisib program and supports its potential as a frontline therapy in a large market. Traders should monitor upcoming regulatory interactions and the initiation of the Phase 3 trial as key value inflection points. The strong tolerability profile differentiates it from prior PI3K inhibitors and increases commercial viability.
Price Chart
Executive Summary
Relay Therapeutics announced plans to advance its zovegalisib + atirmociclib + endocrine therapy triplet into a Phase 3 trial for frontline HR+/HER2- metastatic breast cancer based on strong early data showing a 44% ORR in heavily pre-treated patients. The combination demonstrated favorable tolerability, with low discontinuation and dose reduction rates, supporting its potential as a best-in-class regimen. A supply agreement with Pfizer secures access to atirmociclib for the planned trial.
Key Facts
- Zovegalisib + atirmociclib + fulvestrant showed a 44% objective response rate (ORR) in 34 evaluable, heavily pre-treated patients with PI3Kα-mutated HR+/HER2- metastatic breast cancer.
- Only 3% of patients discontinued due to treatment-related adverse events (TRAEs), and grade 3+ TRAEs occurred in 40%, with no febrile neutropenia.
- Phase 3 trial in frontline patients is expected to start in early 2027, pending regulatory feedback, with a randomized design comparing the triplet to standard CDK4/6 inhibitor + AI.
- Pfizer will supply both atirmociclib (for the experimental arm) and palbociclib (for the control arm) under a clinical supply agreement.
- 77% of patients (48/62) remain on treatment as of the April 13, 2026 data cutoff, with a median follow-up of 7.4 months.
Financial Impact
High-value late-stage clinical catalyst: potential blockbuster in a ~140,000-patient U.S. frontline market; deal value not disclosed but de-risked development via Pfizer supply agreement.
Risk Factors
- Phase 3 trial has not yet started; regulatory feedback could delay or alter the design.
- Interim data may not predict final outcomes; longer follow-up needed for progression-free survival.
- Competition from existing CDK4/6 inhibitors and emerging PI3Kα therapies remains intense.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3281389 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $18.66 $18.84 | ▲ +0.96% | ▲ +1.62% | $18.96 (+1.61%) |
Aug 28, 2026 5w ago | Insider Cluster | $18.77 $19.04 | ▼ −1.44% | ▼ −1.33% | $18.96 (−1.01%) |
Aug 18, 2026 6w ago | Insider Cluster | $20.61 $20.57 | ▲ +0.19% | ▼ −0.01% | $18.96 (+8.01%) |
Jul 8, 2026 12w ago | Insider Cluster | $19.63 $19.08 | ▼ −2.80% | ▼ −3.66% | $18.96 (−3.41%) |
Jun 22, 2026 14w ago | 144 | $17.44 $19.74 | ▲ +13.19% | ▲ +12.18% | $18.96 (+8.72%) |
Jun 12, 2026 16w ago | Institutional Cluster | $14.81 $15.88 | ▲ +7.22% | ▲ +6.55% | $18.96 (+28.02%) |
May 21, 2026 19w ago | 8-K | $13.53 $14.26 | ▼ −5.40% | ▼ −3.74% | $18.96 (−40.13%) |
May 21, 2026 19w ago | Press Release | $13.66 $14.05 | ▼ −2.86% | ▼ −1.01% | $18.96 (−38.80%) |
May 19, 2026 19w ago | 424B5 | $13.02 $13.90 | ▼ −6.76% | ▼ −4.96% | $18.96 (−45.62%) |
May 19, 2026 19w ago | Press Release | $13.02 $14.43 | ▼ −10.83% | ▼ −9.59% | $18.96 (−45.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access